EW - Edwards Lifesciences: It's Expensive But It's Recession-Proof
Introduction
Edwards Lifesciences Corp. (EW) provides products used to treat heart disease and critical care monitoring. The company's products are available in the United States and internationally.
Edwards Lifesciences has a solid history of earnings growth with a boost to earnings expected for 2019 due to the release a new medical software product. The company is efficiently run, and management actively seeks out opportunities to further increase its earnings.
The stock is expensive with high PEG and PE multiples, but it's essentially recession-proof by the nature of its products, which are considered to be essential.